These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9444548)

  • 21. Comparison of the effects of the M1-receptor antagonist telenzepine and the CCK-receptor antagonist loxiglumide on the pancreatic secretory response to intraduodenal tryptophan in dogs.
    Teyssen S; Niebergall-Roth E; Rausch A; Beglinger C; Riepl RL; Chari S; Singer MV
    Pancreas; 1996 Nov; 13(4):407-16. PubMed ID: 8899802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
    Jia D; Yamamoto M; Otsuki M
    World J Gastroenterol; 2015 Jul; 21(25):7742-53. PubMed ID: 26167074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
    Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of a cholecystokinin receptor antagonist (loxiglumide) on gallbladder contractile function in guinea pigs.
    Tsubo K; Arai M; Omachi H; Mitamura K
    J Gastroenterol; 1996 Aug; 31(4):578-81. PubMed ID: 8844481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
    Shiratori K; Takeuchi T; Satake K; Matsuno S;
    Pancreas; 2002 Jul; 25(1):e1-5. PubMed ID: 12131781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of cholecystokinin receptor blockade on circulating concentrations of glucose, insulin, C-peptide, and pancreatic polypeptide after various meals in healthy human volunteers.
    Niederau C; Schwarzendrube J; Lüthen R; Niederau M; Strohmeyer G; Rovati L
    Pancreas; 1992; 7(1):1-10. PubMed ID: 1557335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevation of feed intake in parasite-infected lambs by central administration of a cholecystokinin receptor antagonist.
    Dynes RA; Poppi DP; Barrell GK; Sykes AR
    Br J Nutr; 1998 Jan; 79(1):47-54. PubMed ID: 9505802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of proglumide on cholecystokinin-8-induced exocrine and endocrine pancreatic responses in conscious sheep.
    Mineo H; Iwaki N; Kogishi K; Onaga T; Kato S; Zabielski R
    Comp Biochem Physiol A Physiol; 1997 Nov; 118(3):759-64. PubMed ID: 9406447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cholecystokinin receptor antagonist, loxiglumide, stimulates biliary secretion in conscious rats.
    Watanabe N; Otsuki M
    Eur J Pharmacol; 1994 Nov; 264(3):331-6. PubMed ID: 7698173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different inhibitory effects of the newly developed CCK receptor antagonists FK480 and KSG-504 on pancreatic exocrine and endocrine secretion in the isolated perfused rat pancreas.
    Kihara Y; Otsuki M
    Pancreas; 1995 Mar; 10(2):109-17. PubMed ID: 7716133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini].
    Fujii M; Otsuki M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
    Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):77-82. PubMed ID: 2471851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
    Kimura K; Tominaga K; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids.
    Koop I; Schindler M; Bosshammer A; Scheibner J; Stange E; Koop H
    Gut; 1996 Nov; 39(5):661-7. PubMed ID: 9026479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of CCK on pancreatic function and morphology.
    Niederau C; Lüthen R; Heintges T
    Ann N Y Acad Sci; 1994 Mar; 713():180-98. PubMed ID: 8185159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.
    Fried M; Erlacher U; Schwizer W; Löchner C; Koerfer J; Beglinger C; Jansen JB; Lamers CB; Harder F; Bischof-Delaloye A
    Gastroenterology; 1991 Aug; 101(2):503-11. PubMed ID: 2065926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic secretory and trophic response to caerulein in rats: effect of proglumide and lorglumide.
    Varga G; Papp M; Scarpignato C
    Fundam Clin Pharmacol; 1989; 3(3):295-306. PubMed ID: 2475419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas.
    Okabayashi Y; Otsuki M; Nakamura T; Fujii M; Tani S; Fujisawa T; Koide M; Hasegawa H; Baba S
    Pancreas; 1990 May; 5(3):291-7. PubMed ID: 2188254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effects of the cholecystokinin antagonist loxiglumide on pancreatic exocrine secretion and pancreatic growth in conscious rats.
    Taguchi S; Green GM; Nakano I; Hatta Y
    Int J Pancreatol; 1992 Apr; 11(2):67-73. PubMed ID: 1607730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
    Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of KSG-504, a new cholecystokinin-A-receptor antagonist, on pancreatic exocrine and endocrine secretions in rats.
    Yamazaki Y; Akahane M; Kobayashi M; Takeda H; Ajisawa Y
    Jpn J Pharmacol; 1996 Feb; 70(2):183-90. PubMed ID: 8866756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.